Ampelopsin Inhibits Breast Cancer Glucose Metabolism Reprogramming Based on Network Pharmacology and Molecular Docking

Background: Breast cancer (BC) is the most frequent type of gynecology tumors with high morbidity and mortality. Ampelopsin, main active compound Ampelopsis grossedentata, exerts an anti-tumor effect on a variety cancers. However, anti-cancer role ampelopsin in BC remains unclear. The aim this study to explore mechanism against breast cancer. Materials Methods: target genes treatment were determined analyzed by network pharmacology molecular docking. Cytoscape software was used identify core construct protein–protein interaction (PPI) network. Discovery Studio perform docking glycolytic metabolic enzymes. Results: In total, 25 potential screened out. AKT1, ESR1, ESR2, NCOA1, HSP90AA1, NCOA2, BECN1, COMT, HMOX1, CDK6, ESR1 ESR2 considered as key proteins. Kyoto Encyclopedia Genes Genomes (KEGG) analysis showed that inhibited via modulating estrogen signaling pathway, apoptosis regulation, carbohydrate metabolism, inflammation. Molecular possessed stable binding ability regulate three proteins enzymes such ALDOA LDHA. Conclusions: Ampelopsin may inhibit proliferation cells acting AKT estrogen-related glucose pathways inhibiting involved glycolysis oxidative phosphorylation.